These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 32797372)

  • 41. Inebilizumab reduces neuromyelitis optica spectrum disorder risk independent of FCGR3A polymorphism.
    Kim HJ; Aktas O; Patterson KR; Korff S; Kunchok A; Bennett JL; Weinshenker BG; Paul F; Hartung HP; Cimbora D; Smith MA; Mittereder N; Rees WA; She D; Cree BAC
    Ann Clin Transl Neurol; 2023 Dec; 10(12):2413-2420. PubMed ID: 37804003
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Inebilizumab in AQP4-Ab-positive neuromyelitis optica spectrum disorder.
    Siebert N; Duchow A; Paul F; Infante-Duarte C; Bellmann-Strobl J
    Drugs Today (Barc); 2021 May; 57(5):321-336. PubMed ID: 34061127
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A safe change from eculizumab to satralizumab in a patient with neuromyelitis optica spectrum disorder.
    Funakoshi K; Suzuki K
    Neurol Sci; 2023 Mar; 44(3):1097-1098. PubMed ID: 36350454
    [No Abstract]   [Full Text] [Related]  

  • 44. AQP4-IgG-seropositive neuromyelitis optica spectrum disorder (NMOSD) coexisting with anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis: A case report and literature review.
    Tao S; Zhang Y; Ye H; Guo D
    Mult Scler Relat Disord; 2019 Oct; 35():185-192. PubMed ID: 31398657
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Neuromyelitis Optica Spectrum Disorder].
    Misu T
    Brain Nerve; 2021 May; 73(5):475-482. PubMed ID: 34006678
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Recent progress in maintenance treatment of neuromyelitis optica spectrum disorder.
    Holmøy T; Høglund RA; Illes Z; Myhr KM; Torkildsen Ø
    J Neurol; 2021 Dec; 268(12):4522-4536. PubMed ID: 33011853
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Targeting Neuromyelitis Optica Pathogenesis: Results from Randomized Controlled Trials of Biologics.
    Cacciaguerra L; Tortorella P; Rocca MA; Filippi M
    Neurotherapeutics; 2021 Jul; 18(3):1623-1636. PubMed ID: 33909234
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Safety and efficacy of interleukin-6-receptor inhibitors in the treatment of neuromyelitis optica spectrum disorders: a meta-analysis.
    Kharel S; Shrestha S; Ojha R; Guragain N; Ghimire R
    BMC Neurol; 2021 Nov; 21(1):458. PubMed ID: 34814882
    [TBL] [Abstract][Full Text] [Related]  

  • 49. New therapies for neuromyelitis optica spectrum disorder.
    Levy M; Fujihara K; Palace J
    Lancet Neurol; 2021 Jan; 20(1):60-67. PubMed ID: 33186537
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Editorial on: Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder.
    Pardo S; Giovannoni G; Hawkes C; Lechner-Scott J; Waubant E; Levy M
    Mult Scler Relat Disord; 2019 Aug; 33():A1-A2. PubMed ID: 31324299
    [No Abstract]   [Full Text] [Related]  

  • 51. Long-term safety of satralizumab in NMOSD.
    Lemprière S
    Nat Rev Neurol; 2022 Sep; 18(9):510. PubMed ID: 35941197
    [No Abstract]   [Full Text] [Related]  

  • 52. Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study.
    Pittock SJ; Lennon VA; McKeon A; Mandrekar J; Weinshenker BG; Lucchinetti CF; O'Toole O; Wingerchuk DM
    Lancet Neurol; 2013 Jun; 12(6):554-62. PubMed ID: 23623397
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Benefits of eculizumab in AQP4+ neuromyelitis optica spectrum disorder: Subgroup analyses of the randomized controlled phase 3 PREVENT trial.
    Palace J; Wingerchuk DM; Fujihara K; Berthele A; Oreja-Guevara C; Kim HJ; Nakashima I; Levy M; Terzi M; Totolyan N; Viswanathan S; Wang KC; Pace A; Yountz M; Miller L; Armstrong R; Pittock S;
    Mult Scler Relat Disord; 2021 Jan; 47():102641. PubMed ID: 33310418
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Sarilumab: First Global Approval.
    Scott LJ
    Drugs; 2017 Apr; 77(6):705-712. PubMed ID: 28290137
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Real-world management of patients with neuromyelitis optica spectrum disorder using satralizumab: Results from a Japanese claims database.
    Nakashima I; Nakahara J; Yasunaga H; Yamashita M; Nishijima N; Satomura A; Nio M; Fujihara K
    Mult Scler Relat Disord; 2024 Apr; 84():105502. PubMed ID: 38401202
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Neuromyelitis optica spectrum disorder after treatment with pembrolizumab.
    Shimada T; Hoshino Y; Tsunemi T; Hattori A; Nakagawa E; Yokoyama K; Hattori N
    Mult Scler Relat Disord; 2020 Jan; 37():101447. PubMed ID: 31655267
    [TBL] [Abstract][Full Text] [Related]  

  • 57. New BBB Model Reveals That IL-6 Blockade Suppressed the BBB Disorder, Preventing Onset of NMOSD.
    Takeshita Y; Fujikawa S; Serizawa K; Fujisawa M; Matsuo K; Nemoto J; Shimizu F; Sano Y; Tomizawa-Shinohara H; Miyake S; Ransohoff RM; Kanda T
    Neurol Neuroimmunol Neuroinflamm; 2021 Nov; 8(6):. PubMed ID: 34667128
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Memantine ameliorates motor impairments and pathologies in a mouse model of neuromyelitis optica spectrum disorders.
    Yick LW; Tang CH; Ma OK; Kwan JS; Chan KH
    J Neuroinflammation; 2020 Aug; 17(1):236. PubMed ID: 32782018
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prevalence of anti-aquaporin 4 antibody in a diagnostic cohort of patients being investigated for possible neuromyelitis optica spectrum disorder in Western Australia.
    Fabis-Pedrini MJ; Bundell C; Wee CK; Lucas M; McLean-Tooke A; Mastaglia FL; Carroll WM; Kermode AG
    J Neuroimmunol; 2018 Nov; 324():76-80. PubMed ID: 30248527
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Monoclonal antibody therapy for neuromyelitis optica spectrum disorder: current and future.
    Lin J; Xue B; Li X; Xia J
    Int J Neurosci; 2017 Aug; 127(8):735-744. PubMed ID: 27680606
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.